[2]
Marcos, A.E. The global situation of MDR-TB. Tuberc, 2003, 83, 44-51.
[3]
Caminero, J.A.; Sotgiu, G.; Zumla, A.; Migliori, G.B. Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis. Lancet. Infect. Dis., 2010, 10(9), 621-629.
[4]
Hu, Y.; Xu, L.; He, Y.L.; Pang, Y.; Lu, N.; Liu, J.; Shen, J.; Zhu, D.M.; Feng, X.; Wang, Y.W.; Yang, C. Prevalence and molecular characterization of second-line drugs resistance among multidrug-resistant Mycobacterium tuberculosis isolates in southwest of China. BioMed Res. Int., 2017, 2017, 4563826.
[5]
Parida, S.K.; Axelsson-Robertson, R.; Rao, M.V.; Singh, N.; Master, I.; Lutckii, A.; Keshavjee, S.; Andersson, J.; Zumla, A.; Maeurer, M. Totally drug-resistant tuberculosis and adjunct therapies. J. Intern. Med., 2015, 277(4), 388-405.
[6]
Cox, E.; Laessig, K. FDA approval of bedaquiline - the benefit–risk balance for drug-resistant Tuberculosis. N. Engl. J. Med., 2014, 371(8), 689-691.
[7]
Barry Iii, C.E. Timing is everything for compassionate use of delamanid. Nat. Med., 2015, 21(3), 211.
[8]
Venugopala, K.N.; Krishnappa, M.; Nayak, S.K.; Subrahmanya, B.K.; Vaderapura, J.P.; Chalannavar, R.K.; Gleiser, R.M.; Odhav, B. Synthesis and antimosquito properties of 2,6-substituted benzo[d]thiazole and 2,4-substituted benzo[d]thiazole analogues against Anopheles arabiensis. Eur. J. Med. Chem., 2013, 65, 295-303.
[9]
Rida, S.M.; Youssef, A.M.; Badr, M.H.; Malki, A.; Sherif, Z.A.; Sultan, A.S. Design, synthesis and evaluation of novel benzimidazoles, benzothiazoles and benzofurans incorporating pyrazole moiety as antiangiogenic agents. Arzneim, 2012, 62(2), 63-74.
[10]
Shaikh, F.M.; Patel, N.B.; Sanna, G.; Busonera, B.; Colla, P.; Rajani, D.P. Synthesis of some new 2-amino-6-thiocyanato benzothiazole derivatives bearing 2,4-thiazolidinediones and screening of their in vitro antimicrobial, antitubercular and antiviral activities. Med. Chem. Res., 2015, 24(8), 3129-3142.
[11]
Singh, M.; Gangwar, M.; Nath, G.; Singh, S.K. Synthesis, DNA cleavage and antimicrobial activity of 4-thiazolidinones-benzothiazole conjugates. Ind. J. Exp. Biol., 2014, 52(11), 1062-1070.
[12]
Abuzar, S.; Sharma, S. Synthesis of 6-N-aryl and heteroaryl benzthiazoles as potential anthelmintics. Z. Naturforsch., 1981, 36B(1), 108-111.
[13]
Puranik, N.V.; Puntambekar, H.M.; Srivastava, P. Antidiabetic potential and enzyme kinetics of benzothiazole derivatives and their non-bonded interactions with α-glucosidase and α-amylase. Med. Chem. Res., 2016, 25(4), 805-816.
[14]
Nagoshi, N.; Nakashima, H.; Fehlings, M.G. Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside. Molecules, 2015, 20(5), 7775-7789.
[15]
Shah, F.; Wu, Y.; Gut, J.; Pedduri, Y.; Legac, J.; Rosenthal, P.J.; Avery, M.A. Design, synthesis and biological evaluation of novel benzothiazole and triazole analogs as falcipain inhibitors. MedChemComm, 2011, 2(12), 1201-1207.
[16]
Valcke, A.R.A.; Van Der Flaas, M.A.J. Synergistic compositions containing metconazole and another triazole. In Google Patents:, 1998.
[17]
Reshma, R.S.; Jeankumar, V.U.; Kapoor, N.; Saxena, S.; Bobesh, K.A.; Vachaspathy, A.R.; Kolattukudy, P.E.; Sriram, D. Mycobacterium tuberculosis lysine-varepsilon-aminotransferase a potential target in dormancy: Benzothiazole based inhibitors. Bioorg. Med. Chem., 2017, 25(10), 2761-2771.
[18]
Chikhale, R.; Menghani, S.; Babu, R.; Bansode, R.; Bhargavi, G.; Karodia, N.; Rajasekharan, M.V.; Paradkar, A.; Khedekar, P. Development of selective DprE1 inhibitors: Design, synthesis, crystal structure and antitubercular activity of benzothiazolylpyrimidine-5-carboxamides. Eur. J. Med. Chem., 2015, 96, 30-46.
[19]
Landge, S.; Mullick, A.B.; Nagalapur, K.; Neres, J.; Subbulakshmi, V.; Murugan, K.; Ghosh, A.; Sadler, C.; Fellows, M.D.; Humnabadkar, V.; Mahadevaswamy, J.; Vachaspati, P.; Sharma, S.; Kaur, P.; Mallya, M.; Rudrapatna, S.; Awasthy, D.; Sambandamurthy, V.K.; Pojer, F.; Cole, S.T.; Balganesh, T.S.; Ugarkar, B.G.; Balasubramanian, V.; Bandodkar, B.S.; Panda, M.; Ramachandran, V. Discovery of benzothiazoles as antimycobacterial agents: Synthesis, structure-activity relationships and binding studies with Mycobacterium tuberculosis decaprenylphosphoryl-beta-D-ribose 2′-oxidase. Bioorg. Med. Chem., 2015, 23(24), 7694-7710.
[20]
Mehra, R.; Rajput, V.S.; Gupta, M.; Chib, R.; Kumar, A.; Wazir, P.; Khan, I.A.; Nargotra, A. Benzothiazole derivative as a novel Mycobacterium tuberculosis Shikimate kinase inhibitor: Identification and elucidation of its allosteric mode of inhibition. J. Chem. Inf. Model., 2016, 56(5), 930-940.
[21]
Venugopala, K.N.; Albericio, F.; Coovadia, Y.M.; Kruger, H.G.; Maguire, G.E.M.; Pillay, M.; Govender, T. Total synthesis of a depsidomycin analogue by convergent solid-phase peptide synthesis and macrolactonization strategy for antitubercular activity. J. Pept. Sci., 2011, 17(10), 683-689.
[22]
Venugopala, K.N.; Nayak, S.K.; Pillay, M.; Prasanna, R.; Coovadia, Y.M.; Odhav, B. Synthesis and antitubercular activity of 2-(substituted phenyl/benzyl-amino)-6-(4-chlorophenyl)-5-(met-hoxycarbonyl)-4-methyl-3,6-dihydropyrimidin-1-ium chlorides. Chem. Biol.Drug. Des., 2013, 81(2), 219-227.
[23]
Venugopala, K.N.; Dharma, R.G.B.; Bhandary, S.; Pillay, M.; Chopra, D.; Aldhubiab, B.E.; Attimarad, M.; Alwassil, O.I.; Harsha, S.; Mlisana, K. Design, synthesis, and characterization of (1-(4-aryl)-1H-1,2,3-triazol-4-yl) methyl, substituted phenyl-6-methyl-2-oxo-1,2,3,4-tetrahydropyrimidine-5-carboxylates against Mycobacterium tuberculosis. Drug Des. Devel. Ther., 2016, 10, 2681-2690.
[24]
Khedr, M.A.; Pillay, M.; Chandrashekharappa, S.; Chopra, D.; Aldhubiab, B.E.; Attimarad, M.; Alwassil, O.I.; Mlisana, K.; Odhav, B.; Venugopala, K.N. Molecular modeling studies and anti-TB activity of trisubstituted indolizine analogues; molecular docking and dynamic inputs. J. Biomol. Struct. Dyn., 2018, 36, 2163-2178.
[25]
Palmer, P.J.; Trigg, R.B.; Warrington, J.V. Benzothiazolines as antituberculous agents. J. Med. Chem., 1971, 14(3), 248-251.
[26]
Panini, P.; Venugopala, K.N.; Odhav, B.; Chopra, D. Polymorphism in two biologically active dihydropyrimidinium hydrochloride derivatives: quantitative inputs towards the energetics associated with crystal packing. Acta Crystallogr. B Struct. Sci. Cryst.Sect. B Eng. Mater., 2014, 70, 681-696.
[27]
Panini, P.; Venugopala, K.N.; Odhav, B.; Chopra, D. Quantitative analysis of intermolecular interactions in 7-hydroxy-4-methyl-2H-chromen-2-one and its hydrate. P. Natl. A. Sci. India A., 2014, 84(2), 281-295.
[28]
Munshi, P.; Venugopala, K.N.; Jayashree, B.S.; Guru, R.T.N. Concomitant polymorphism in 3-acetylcoumarin: Role of weak C−H···O and C−H···π interactions. Cryst. Growth Des., 2004, 4(6), 1105-1107.
[29]
Siemens, S.S. Siemens Analytical X-ray Instruments Inc; Madison, MI, 1995.
[30]
Apex2, Version 2 User Manual M86-E01078; Bruker Analytical X-ray Systems Madison: WI, 2006.
[31]
Burla, M.C.; Caliandro, R.; Carrozzini, B.; Cascarano, G.L.; Cuocci, C.; Giacovazzo, C.; Mallamo, M.; Mazzone, A.; Polidori, G. Crystal structure determination and refinement via SIR2014. J. Appl. Cryst., 2015, 48(1), 306-309.
[32]
Sheldrick, G. A short history of SHELX. Acta. Crystallographica. Sec. C., 2015, 71, 3-8.
[33]
Farrugia, L. WinGX suite for small-molecule single-crystal crystallography. J. Appl. Cryst., 1999, 32(4), 837-838.
[34]
Sheldrick, G.M. SHELXS-97, SHELXL-2014 and SADABS version 2.05; University of Göttingen: Germany, 1997.
[35]
Macrae, C.F.; Bruno, I.J.; Chisholm, J.A.; Edgington, P.R.; McCabe, P.; Pidcock, E.; Rodriguez-Monge, L.; Taylor, R.; van de Streek, J.; Wood, P.A. Mercury CSD 2.0 - new features for the visualization and investigation of crystal structures. J. Appl. Cryst., 2008, 41(2), 466-470.
[36]
Nardelli, M. PARST95 - an update to PARST: a system of Fortran routines for calculating molecular structure parameters from the results of crystal structure analyses. J. Appl. Cryst., 1995, 28(5), 659.
[37]
Spek, A. Single-crystal structure validation with the program PLATON. J. Appl. Cryst., 2003, 36(1), 7-13.
[38]
Martin, A.; Morcillo, N.; Lemus, D.; Montoro, E.; Telles, M.A.; Simboli, N.; Pontino, M.; Porras, T.; Leon, C.; Velasco, M.; Chacon, L.; Barrera, L.; Ritacco, V.; Portaels, F.; Palomino, J.C. Multicenter study of MTT and resazurin assays for testing susceptibility to first-line anti-tuberculosis drugs. Int. J. Tuberc. Lung Dis., 2005, 9(8), 901-906.
[39]
Friesner, R.A.; Banks, J.L.; Murphy, R.B.; Halgren, T.A.; Klicic, J.J.; Mainz, D.T.; Repasky, M.P.; Knoll, E.H.; Shelley, M.; Perry, J.K.; Shaw, D.E.; Francis, P.; Shenkin, P.S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J. Med. Chem., 2004, 47(7), 1739-1749.
[40]
Tripathi, S.M.; Agarwal, A.; Ramachandran, R. Mutational analysis of Mycobacterium tuberculosis lysine varepsilon-aminotransferase and inhibitor co-crystal structures, reveals distinct binding modes. Biochem. Biophys. Res. Commun., 2015, 463(1-2), 154-160.
[41]
Tripathi, S.M.; Ramachandran, R. Direct evidence for a glutamate switch necessary for substrate recognition: crystal structures of lysine ε-aminotransferase (Rv3290c) from Mycobacterium tuberculosis H37Rv. J. Mol. Biol., 2006, 362, 877-886.
[42]
Batt, S.M.; Jabeen, T.; Bhowruth, V.; Quill, L.; Lund, P.A.; Eggeling, L.; Alderwick, L.J.; Futterer, K.; Besra, G.S. Structural basis of inhibition of Mycobacterium tuberculosis DprE1 by benzothiazinone inhibitors. Proc. Natl. Acad. Sci. USA, 2012, 109(28), 11354-11359.
[43]
Blanco, B.; Prado, V.; Lence, E.; Otero, J.M.; Garcia-Doval, C.; van Raaij, M.J.; Llamas-Saiz, A.L.; Lamb, H.; Hawkins, A.R.; González-Bello, C. Mycobacterium tuberculosis Shikimate kinase inhibitors: Design and simulation studies of the catalytic turnover. J. Am. Chem. Soc., 2013, 135(33), 12366-12376.
[44]
Alnazawi, M.; Altaher, A.; Kandeel, M. Comparative genomic analysis MERS CoV i solated from humans and camels with special reference to virus encoded helicase. Biol. Pharm. Bull., 2017, 40(8), 1289-1298.
[45]
Kandeel, M.; Kitade, Y. In silico molecular docking analysis of the human Argonaute 2 PAZ domain reveals insights into RNA interference. J. Comput. Aided Mol. Des., 2013, 27(7), 605-614.
38
4
1